Hypothalamic POMC or MC4R deficiency impairs counterregulatory responses to hypoglycemia in mice

Benjamin P Tooke1, Hui Yu2, Jessica M Adams3

  • 1Case Western Reserve University, Cleveland, OH, USA; Department of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI, USA.

Molecular Metabolism
|December 4, 2018
PubMed
Abstract

Insights

Hypoglycemia counterregulation is impaired in diabetes due to reduced hypothalamic proopiomelanocortin (POMC) and melanocortin 4 receptor (MC4R). Enhancing MC4R function may improve responses in diabetic patients.

Area of Science:

  • Neuroendocrinology
  • Metabolic Regulation
  • Diabetes Pathophysiology

Background:

  • Life-threatening hypoglycemia is a significant complication in diabetes management.
  • Impaired counterregulatory responses to hypoglycemia in diabetes are known but molecular mechanisms are unclear.
  • The hypothalamic proopiomelanocortin (POMC)/melanocortin 4 receptor (MC4R) circuit regulates sympathetic nervous system (SNS) activity, crucial for counterregulation.

Purpose of the Study:

  • To investigate the role of hypothalamic POMC and MC4R in counterregulatory responses to hypoglycemia.
  • To elucidate the molecular mechanisms underlying impaired counterregulation in diabetes.
  • To explore the therapeutic potential of MC4R agonists in restoring counterregulatory function.

Main Methods:

  • Generated POMC- and MC4R-deficient mice in specific hypothalamic nuclei (ARC/PVH).
  • Induced hypoglycemia/glucopenia to measure counterregulatory hormone release.
  • Assessed Pomc and Mc4r mRNA levels in diabetic mouse models (STZ-induced T1D, NOD).
  • Administered MC4R agonist (MTII) into the PVH of diabetic mice.

Main Results:

  • POMC- and MC4R-deficient mice showed diminished epinephrine and glucagon release during hypoglycemia.
  • Diabetic mice exhibited reduced hypothalamic Pomc and Mc4r expression, correlating with impaired counterregulation.
  • Insulin treatment normalized glycemia but did not restore counterregulatory function.
  • PVH administration of an MC4R agonist restored counterregulatory responses in diabetic mice.

Conclusions:

  • Hypothalamic POMC and MC4R are essential for normal counterregulatory responses to hypoglycemia.
  • Reduced POMC and MC4R expression in type 1 diabetes contributes to impaired hypoglycemia defense.
  • Enhancing MC4R function represents a potential therapeutic strategy to improve hypoglycemia counterregulation in diabetes.

Related Concept Videos

Hypothalamic-Pituitary Axis01:37

Hypothalamic-Pituitary Axis

The response to stress—be it physical or psychological, acute or chronic—involves activation of the Hypothalamic-Pituitary-Adrenal (HPA) axis. The HPA axis is part of the neuroendocrine system because it involves both neuronal and hormonal communication. Its function is to regulate homeostatic systems—metabolic, cardiovascular, and immune—providing the necessary means to respond to a stressor.
66.1K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
983
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
463
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Responses to Gravity and Touch02:26

Responses to Gravity and Touch

Gravitropism: Plant Responses to Gravity
41.9K
Humoral Immune Responses01:36

Humoral Immune Responses

Overview
83.9K